Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients

Clinical Pharmacokinetics

Volumn 52, Issue 11, 2013, Pages 967-980

  Yee, Donald L ^a   O'Brien, Sarah H ^b   Young, Guy ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; DABIGATRAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CONTINUOUS INFUSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; PEDIATRICS; PHARMACOGENETICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CHILD; HEPARIN; HUMANS; POLYSACCHARIDES; THROMBOSIS; VITAMIN K;

EID: 84886803806     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0094-1     Document Type: Review

References (101)

1. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-8.
2. Stein PD, Kayali F, Olson RE. Incidence of venous thromboembolism in infants and children: data from the National Hospital Discharge Survey. J Pediatr. 2004;145(4):563-5.
3. Vu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg. 2008;43(6):1095-9.
4. Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Gottl U, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S-801S.
5. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74(1):415-25.
6. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, et al. Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95(2):362-72.
7. Ko RH, Young G. Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children. Expert Rev Clin Pharmacol. 2012;5(4):389-96.
8. Young G. Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med. 2011;16(6):349-54.
9. Young G. New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res. 2011;127(2):70-4.
10. Kozul C, Newall F, Monagle P, Mertyn E, Ignjatovic V. A clinical audit of antithrombin concentrate use in a tertiary paediatric centre. J Paediatr Child Health. 2012;48(8):681-4.
11. Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics. 2009;123(3):e510-8.
12. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis. 2000;11(2):137-44.
13. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res. 2007;120(3):347-51.
14. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, et al. Clinical use of unfractionated heparin therapy in children: time for change? Br J Haematol. 2010;150(6):674-8.
15. Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet. 1980;5(3):204-20.
16. Newall F, Ignjatovic V, Johnston L, Lane G, Summerhayes R, Cranswick N, et al. Unfractionated heparin has an age-dependent pharmacokinetic profile in children. J Thromb Haemost. 2009;7(s2):774.
17. McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. Pediatr Res. 1981;15(7):1015-8.
18. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, et al. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost. 2010;103(5):1085-90.
19. Guzzetta NA, Miller BE, Todd K, Szlam F, Moore RH, Tosone SR. An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg. 2005;100(5):1276-82 (table).
20. Newall F, Ignjatovic V, Summerhayes R, Gan A, Butt W, Johnston L, et al. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res. 2009;123(5):710-4.
21. Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost. 2010;8(6):1290-4.
22. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):188S-203S.
23. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost. 2006;4(10):2280-2.
24. Schechter T, Finkelstein Y, Ali M, Kahr WH, Williams S, Chan AK, et al. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels. J Thromb Haemost. 2012;10(3):368-74.
25. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res. 1994;35(1):78-83.
26. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, et al. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica. 2007;92(4):554-7.
27. Chan AK, Black L, Ing C, Brandao LR, Williams S. Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res. 2008;122(1):135-6.
28. Newall F, Chan AK, Ignjatovic V, Monagle P. Recommendations for developing uniform laboratory monitoring of heparinoid anticoagulants in children. J Thromb Haemost. 2012;10(1):145-7.
29. Taylor BN, Bork SJ, Kim S, Moffett BS, Yee DL. Evaluation of weight-based dosing of unfractionated heparin in obese children. J Pediatr. 2013. In Press.
30. Guzzetta NA, Amin SJ, Tosone AK, Miller BE. Change in heparin potency and effects on the activated clotting time in children undergoing cardiopulmonary bypass. Anesth Analg. 2012;115(4):921-4.
31. Martindale SJ, Shayevitz JR, D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 1996;10(4):458-63.
32. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost. 1994;72(6):836-42.
33. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79(1):1-17.
34. Nowak-Gottl U, Bidlingmaier C, Krumpel A, Gottl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008;153(6):1120-7.
35. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26(Suppl 1):31-8.
36. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128(3):313-8.
37. Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol. 2000;22(2):137-42.
38. Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost. 2005;94(6):1164-71.
39. O'Brien SH, Lee H, Ritchey AK. Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study. J Thromb Haemost. 2007;5(9):1985-7.
40. Sanderink GJ, Le LA, Jariwala N, Harding N, Ozoux ML, Shukla U, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72(3):308-18.
41. Trame MN, Mitchell L, Krumpel A, Male C, Hempel G, Nowak-Gottl U. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study. J Thromb Haemost. 2010;8(9):1950-8.
42. Schobess R, During C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Gottl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica. 2006;91(12):1701-4.
43. Laporte S, Mismetti P, Piquet P, Doubine S, Touchot A, Decousus H. Population pharmacokinetic of nadroparin calcium (Fraxiparine) in children hospitalised for open heart surgery. Eur J Pharm Sci. 1999;8(2):119-25.
44. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res. 2003;109(2-3):93-9.
45. Bontadelli J, Moeller A, Schmugge M, Schraner T, Kretschmar O, Bauersfeld U, et al. Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease. Intensive Care Med. 2007;33(11):1978-84.
46. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136(4):439-45.
47. Merkel N, Gunther G, Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol. 2006;115(3-4):230-6.
48. Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr. 1999;158(Suppl 3):S134-9.
49. Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):F365-70.
50. Bauman ME, Belletrutti MJ, Bajzar L, Black KL, Kuhle S, Bauman ML, et al. Evaluation of enoxaparin dosing requirements in infants and children: better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101(1):86-92.
51. Estepp JH, Smeltzer M, Reiss UM. The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children. Pediatr Blood Cancer. 2012;59(1):105-9.
52. Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. J Pediatr Hematol Oncol. 2004;26(9):561-6.
53. Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children. Br J Haematol. 2010;149(5):734-8.
54. Lulic-Botica M, Rajpurkar M, Sabo C, Tutag-Lehr V, Natarajan G. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis. Acta Paediatr. 2012;101(4):e147-50.
55. Malowany JI, Knoppert DC, Chan AK, Pepelassis D, Lee DS. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy. 2007;27(9):1263-71.
56. Michaels LA, Gurian M, Hegyi T, Drachtman RA. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics. 2004;114(3):703-7.
57. Malowany JI, Monagle P, Knoppert DC, Lee DS, Wu J, McCusker P, et al. Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thromb Res. 2008;122(6):826-30.
58. Ignjatovic V, Summerhayes R, Newall F, Monagle P. The in vitro response to low-molecular-weight heparin is not age-dependent in children. Thromb Haemost. 2010;103(4):855-6.
59. Richard AA, Kim S, Moffett BS, Bomgaars L, Mahoney D Jr, Yee DL. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013;162(2):293-6.
60. Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R, et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost. 1994;71(3):265-9.
61. Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94(9):3007-14.
62. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP, et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost. 2003;1(8):1740-3.
63. Woods A, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA. Antithrombotic therapy in children and adolescents. Thromb Res. 1986;42(3):289-301.
64. Piquet P, Losay J, Doubine S. Acenocoumarol (Sintrom) and fluinidione (Previscan) in pediatrics after cardiac surgical procedures. Arch Pediatr. 2002;9(11):1137-44.
65. Gunther T, Mazzitelli D, Schreiber C, Wottke M, Paek SU, Meisner H, et al. Mitral-valve replacement in children under 6 years of age. Eur J Cardiothorac Surg. 2000;17(4):426-30.
66. Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, et al. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116(26):6101-5.
67. Wermes C, Bergmann F, Reller B, Sykora KW. Severe protein C deficiency and aseptic osteonecrosis of the hip joint: a case report. Eur J Pediatr. 1999;158(Suppl 3):S159-61.
68. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119(3):861-7.
69. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974;16(2):348-54.
70. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet. 1986;11(6):483-504.
71. Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, Kashima T, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68(5):541-55.
72. Doyle JJ, Koren G, Cheng MY, Blanchette VS. Anticoagulation with sodium warfarin in children: effect of a loading regimen. J Pediatr. 1988;113(6):1095-7.
73. Massicotte P, Leaker M, Marzinotto V, Adams M, Freedom R, Williams W, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost. 1998;80(4):570-4.
74. Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012;119(3):868-73.
75. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965-74.
76. Murry DJ, Crom WR, Reddick WE, Bhargava R, Evans WE. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos. 1995;23(10):1110-6.
77. Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol. 2011;58(3):228-39.
78. Biss TT, Adamson AJ, Seal CJ, Kamali F. The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin. Pediatr Hematol Oncol. 2011;28(5):425-7.
79. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106-12.
80. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation. 2011;124(23):2554-9.
81. Biss T, Hamberg AK, Avery P, Wadelius M, Kamali F. Warfarin dose prediction in children using pharmacogenetics information. Br J Haematol. 2012;159(1):106-9.
82. Biss TT, Avery PJ, Williams MD, Brandao LR, Grainger JD, Kamali F. VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children. J Thromb Haemost. 2013;11(2):373-5.
83. Kato Y, Ichida F, Saito K, Watanabe K, Hirono K, Miyawaki T, et al. Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet. 2011;26(3):295-9.
84. Kosaki K, Yamaghishi C, Sato R, Semejima H, Fuijita H, Tamura K, et al. 1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr Cardiol. 2006;27(6):685-8.
85. Ruud E, Holmstrom H, Bergan S, Wesenberg F. Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. Pediatr Blood Cancer. 2008;50(3):710-3.
86. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-64.
87. Biss TT, Kamali F. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing? Pharmacogenomics. 2012;13(11):1211-4.
88. Cetta F, Graham LC, Wrona LL, Arruda MJ, Walenga JM. Argatroban use during pediatric interventional cardiac catheterization. Catheter Cardiovasc Interv. 2004;61(1):147-9.
89. Deitcher SR, Topoulos AP, Bartholomew JR, Kichuk-Chrisant MR. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr. 2002;140(2):264-6.
90. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am. 2000;14(2):445-57, x.
91. Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost. 2002;28(5):447-54.
92. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost. 2007;5(8):1654-9.
93. O'Brien SH, Yee DL, Lira J, Goldenberg NA, Young G. Prospective, open-label clinical trial of bivalirudin in children with venous thromboembolism. Blood. 2012;120(21).
94. Forbes TJ, Hijazi ZM, Young G, Ringewald JM, Aquino PM, Vincent RN, et al. Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv. 2011;77(5):671-9.
95. Young G, Boshkov LK, Sullivan JE, Raffini LJ, Cox DS, Boyle DA, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer. 2011;56(7):1103-9.
96. Madabushi R, Cox DS, Hossain M, Boyle DA, Patel BR, Young G, et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol. 2011;51(1):19-28.
97. Boshkov LK, Kirby A, Shen I, Ungerleider RM. Recognition and management of heparin-induced thrombocytopenia in pediatric cardiopulmonary bypass patients. Ann Thorac Surg. 2006;81(6):S2355-9.
98. Sharathkumar AA, Crandall C, Lin JJ, Pipe S. Treatment of thrombosis with fondaparinux (Arixtra) in a patient with end-stage renal disease receiving hemodialysis therapy. J Pediatr Hematol Oncol. 2007;29(8):581-4.
99. Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011;57(6):1049-54.
100. Ko RH, Michieli C, Bernardini L, Young G. FondaKids II: long-term follow-up data of children receiving fondaparinux for treatment of venous thrombotic events. Blood. 2012;120(21).
101. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.